epocrates logo
epocrates logo
epocrates logo
  • 0

Journal Article Synopsis

Reg Anesth Pain Med

Standardized ketamine infusion shows promise for chronic refractory pain

October 16, 2025

card-image

Given its high treatment adherence and sustained symptom relief, ketamine may be a viable non-opioid option for patients who have exhausted conventional therapies for chronic refractory pain. Further prospective studies are needed to refine protocols and identify optimal candidates for treatment.

Study details: This retrospective observational study included 1,034 adults with chronic refractory pain treated at a multidisciplinary outpatient pain clinic using a standardized ketamine infusion protocol (0.5 mg/kg over 40 minutes, daily for five days). Effectiveness was assessed via patient-reported outcomes (PROs) at baseline, post-treatment, and at 3- and 6-month follow-up.

Results: Treatment completion was high (86.1%), with no serious adverse events reported. Between 20.3% and 46.4% of patients achieved clinically meaningful improvement in PROs at the end of treatment, with similar proportions at 3 and 6 months. Statistically significant mean improvements were observed in fatigue, pain interference, and social role satisfaction, and these gains were sustained through 6 months. Most individual outcomes didn't reach clinically meaningful thresholds, but group-level improvements were consistent.

Source:

Tankha H, et al. (2025, October 5). Reg Anesth Pain Med. Standardized ketamine infusion protocol for chronic refractory pain: a retrospective study of preliminary effectiveness and treatment completion. https://pubmed.ncbi.nlm.nih.gov/41047247/

Trending icon

TRENDING THIS WEEK

EPOCRATES CME

View Catalog

view all CME activities
learn more about epocrates plus
Clinical FAQ icon

Clinical FAQs

Check out the answers to frequently asked questions about our clinical content.

Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & Feedback
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information